drugset
drugset / Trial / NCT04955886

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04955886 ↗

Phase 2 Unknown 14 enrolled Fujian Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

A prospective, single-arm,mutil-center study to assess the efficacy and safety of Surufatinib combined with Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Timeline

Start
2021-08
Primary completion
2022-08
Completion
2023-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Surufatinib Small molecule 250 mg Oral
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

nasopharyngeal carcinoma